Loading clinical trials...
Loading clinical trials...
Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet 150 mg (Test) and EPIVIR of Glaxosmithkline in Healthy Volunteers of Both Genders in Fasting Condition
Conditions
Interventions
Epivir ® tablet 150-mg single dose (drug reference)
Lamivudine 150-mg tablet single dose (drug test)
Start Date
April 1, 2013
Primary Completion Date
December 1, 2013
Completion Date
December 1, 2013
Last Updated
November 13, 2015
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
Universidade Federal de Pernambuco
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions